Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Completed · Phase 2

Conditions studied: Diabetic Nephropathy

In brief

Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.

Key facts

Study ID

NCT00097955

Run by

Novartis Pharmaceuticals

People needed

496

Starts

2004-10-01

Expected to finish

2007-04-01

Last updated by the study team

2017-05-17

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hypertension
• Elevated urinary protein levels
• Confirmed type 2 diabetes

You may not qualify if…

• Certain diseases
• Uncontrolled diabetes
• Type 1 diabetes

Where it is running

• Investigative Site — Madrid, Spain
• Investigative Site — London, United Kingdom
• Novartis Pharmaceuticals — East Hanover, New Jersey, United States
• Investigative Site — Québec, Canada
• Investigative Site — Hillerød, Denmark
• Investigative Site — Paris, France
• Study site — Investigative Centers, Germany
• Investigative Site — Athens, Greece
• Investigative Site — Rome, Italy
• Investigative Site — Rotterdam, Netherlands
• Investigative Site — Bucharest, Romania
• Investigative Site — Moscow, Russia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.